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Objectives. We sought to characterize the clinical determinants
of mortality in patients with angiographically diagnosed ischemic
or nonischemic cardiomyopathy.
Background. Patients with ischemic cardiomyopathy may have
a worse prognosis than patients with nonischemic cardiomyopa-
thy. Few studies have assessed the effect of ischemic versus
nonischemic etiology on outcomes.
Methods. We analyzed prospectively collected data on 3,787
patients with a left ventricular ejection fraction <240% who
underwent coronary angiography. Patients were considered to
have ischemic cardiomyopathy (n 5 3,112) if they had a history of
myocardial infarction, percutaneous transluminal coronary an-
gioplasty, coronary artery bypass graft surgery or at least one
major epicardial coronary artery with >275% stenosis; all others
were considered to have nonischemic cardiomyopathy (n 5 675).
Results. The median age, ejection fraction and proportion of
patients with New York Heart Association functional class III or
IV symptoms for the nonischemic and ischemic groups were 55
years versus 63 years, 27% versus 32% and 57% versus 25%,
respectively. After adjustment for baseline clinical risk factors
and presenting characteristics, ischemic etiology remained an
important independent predictor of 5-year mortality (p < 0.0001).
The extent of coronary artery disease was a better predictor of
survival than ischemic or nonischemic etiology (log likelihood
chi-square 700 vs. 675, respectively).
Conclusions. Ischemic etiology is a significant independent
predictor of mortality in patients with cardiomyopathy. However,
the extent of coronary artery disease contributes more prognostic
information than the clinical diagnosis of ischemic or nonisch-
emic cardiomyopathy. Further research is needed to refine the
clinical definition of ischemic cardiomyopathy so that physicians
can appropriately prescribe treatment and accurately predict
outcome.
(J Am Coll Cardiol 1997;30:1002–8)
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Patients with left ventricular systolic dysfunction are commonly
divided into two major groups—those with ischemic and
nonischemic cardiomyopathy. Ischemic cardiomyopathy, a re-
sult of the complications of coronary artery disease (CAD) (1),
is one of the most common causes of heart failure in the
Western world (2).
It is important to distinguish between ischemic and nonisch-
emic cardiomyopathy because the diagnosis influences man-
agement. Smoking cessation, lipid-lowering therapy and hor-
mone replacement therapy are important interventions in
patients with ischemic cardiomyopathy. Revascularization in
patients with low ejection fractions and significant CAD is
strongly associated with improved survival (3–5) and should be
considered in all patients with ischemic cardiomyopathy (6). In
addition to risk factor modification and revascularization,
recent clinical trials suggest that the etiology of heart failure
may influence the response to medical therapy. Trials of
amlodipine (6), amiodarone (7,8), bisoprolol (9) and digoxin
(10,11) suggest that patients with ischemic cardiomyopathy
may not respond to medical therapy as favorably as patients
with nonischemic cardiomyopathy. Although differential treat-
ment effects are difficult to interpret owing to potential mis-
classification of heart failure etiology, these findings highlight
the importance of evaluating outcomes in patients with well
established ischemic and nonischemic cardiomyopathy.
To better describe the clinical and angiographic character-
istics and outcomes associated with ischemic versus nonisch-
emic cardiomyopathy, over an 11-year period we evaluated all
patients referred for cardiac catheterization at Duke Univer-
sity Medical Center who had a left ventricular ejection fraction
#40%.
Methods
Patient group. We identified 4,519 patients with a left
ventricular ejection fraction #40% who underwent cardiac
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catheterization at Duke University Medical Center between
January 1984 and January 1995 (Fig. 1). We then excluded
patients with myocardial infarction within 30 days before index
catheterization (n 5 472); primary valvular heart disease, as
defined by severe aortic or pulmonary insufficiency, or severe
stenosis in any heart valve (n 5 246); congenital heart disease
(n 5 14); or previous heart transplantation (n 5 0). After
exclusions, the final study group included 3,787 patients.
Ischemic etiology (n 5 3,112) was defined as left ventricular
dysfunction with previous myocardial infarction, percutaneous
transluminal coronary angioplasty, coronary artery bypass graft
surgery or significant CAD (see discussion of cardiac catheter-
ization) at index catheterization; all other patients were con-
sidered to have nonischemic cardiomyopathy (n 5 675).
Data collection. Baseline variables from each patient’s
clinical history and physical examination were collected pro-
spectively and stored in the Duke Databank for Cardiovascular
Disease (12,13). Follow-up procedures have been described
(13–15). Briefly, follow-up information on ischemic cardiomy-
opathy in patients with significant CAD, coronary angioplasty
or bypass surgery was collected at 6 months, 1 year and
annually after the index cardiac catheterization. Follow-up
information was collected by mailed, self-administered ques-
tionnaires, followed by telephone contact to nonresponders.
Subsequent clinic visits were also monitored to determine
survival status. Identifying information on all patients not
contacted by these methods was submitted to the National
Death Index (16). Death certificates were ordered on all
potential matches, and each death certificate was examined to
confirm the match. The end date for follow-up assessment was
January 1, 1995. The median follow-up time was 5.7 years;
follow-up for the entire study group was 98.4% complete.
Cardiac catheterization. The results of cardiac catheteriza-
tion were prospectively collected (13,15,17,18). Significant
CAD was defined as $75% occlusion of a major epicardial
coronary artery (15). Stenotic lesions were graded subjectively
by visual consensus of at least two experienced observers on
the following ordinal scale: 0%, 25%, 50%, 75%, 95% or 100%
occlusive. The extent of CAD was characterized by the tradi-
tional one-, two- or three-vessel disease classification (19) and
the Coronary Artery Disease Prognostic Index (Table 1)
(14,19). The CAD index accounts for the number of diseased
vessels but also considers left anterior descending coronary
artery disease, the number of 95% diseased vessels, 75% and
95% proximal left anterior descending coronary artery stenosis
and 75% and 95% left main coronary artery stenosis.
Left ventricular ejection fraction was determined by biplane
ventriculography using the modified area–length method (20).
Data analysis. Medians with 25th and 75th percentiles
were calculated for continuous baseline characteristics. Cate-
goric variables are expressed as percentages. We developed
Cox regression models for estimating survival by examining
univariable tests for interactions between baseline characteris-
tics and ischemic etiology. Next, we constructed a multivariable
Cox regression model that included all baseline characteristics
and all significant interaction variables. A final model was
generated that eliminated nonsignificant model components
and retained all significant interactions with ischemic etiology.
All candidate variables were examined graphically to ensure
that their relation with the outcome was modeled appropri-
ately. Nonlinear relations were recoded or transformed to
adhere to model assumptions. The mortality model was devel-
oped without variables relating to the extent of CAD, because
this information is not typically used in the clinical diagnosis of
ischemic cardiomyopathy. Rather, the presence (in contrast to
the extent) of significant CAD commonly results in such a
diagnosis.
To compare the prognostic contribution of ischemic etiol-
ogy to that of the extent of CAD, several models were
developed. The intent of these modeling procedures was to
compare the prognostic contribution of etiology to that of
extent of CAD after adjustment for important clinical charac-
teristics. This is in contrast to the survival model described
Figure 1. Identification of study group. CM 5 cardiomyopathy; EF 5
(left ventricular) ejection fraction; HX 5 history; MI 5 myocardial
infarction.
Table 1. Coronary Artery Disease Prognostic Index*
Extent of CAD Prognostic Weight (0–100)
No CAD $50% 0
1 VD 50% to 74% 19
.1 VD 50% to 74% 23
1 VD (75%) 23
1 VD ($95%) 32
2 VD 37
2 VD (both $95%) 42
1 VD, $95% proximal LAD 48
2 VD, $95% LAD 48
2 VD, $95% proximal LAD 56
3 VD 56
3 VD, $95% in at least one vessel 63
3 VD, 75% proximal LAD 67
3 VD, $95% proximal LAD 74
LMCA (75%) 82
LMCA ($95%) 100
*Note that the Coronary Artery Disease Prognostic Index is hierarchical and
that patients are assigned to the most severe category that applies to them (25).
CAD 5 coronary artery disease; LAD 5 left anterior descending coronary
artery; LMCA 5 left main coronary artery; VD 5 vessel disease.
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earlier—the intent of which was to develop the best predictive
model. The prognostic contribution of etiology and extent of
CAD, as measured by the CAD index, was evaluated by
comparing overall model log likelihood chi-square tests.
We used Kaplan-Meier survival estimates to describe the
survival patterns for all study patients, stratified by disease
etiology and extent of CAD. Patients in the ischemic group
were subdivided into mild (CAD index #42), moderate (CAD
index 48 to 63) and severe CAD (CAD index 67 to 100).
Follow-up time was computed from the index catheterization
date and was based on all-cause mortality. The Cox propor-
tional hazards regression model was used for statistical com-
parison of survival predictors.
Results
Clinical characteristics. The clinical characteristics of pa-
tients with ischemic and nonischemic cardiomyopathy are
shown in Table 2. There were more men in the ischemic cohort
than in the cohort of patients with nonischemic cardiomyopa-
thy. Patients with ischemic cardiomyopathy were older and had
a higher incidence of risk factors commonly associated with
CAD. Patients with nonischemic cardiomyopathy had more
severe heart failure symptoms, lower left ventricular ejection
fractions and symptoms of congestive heart failure for a longer
period before the index cardiac catheterization. A history of
coronary artery revascularization or myocardial infarction was
common in the ischemic group. Typical angina pectoris was
more common in patients with ischemic cardiomyopathy than
in those with nonischemic cardiomyopathy; however, the inci-
dence remained high in the nonischemic cohort (34%).
Angiographic characteristics. The coronary anatomy of
patients with ischemic and nonischemic cardiomyopathy is
shown in Table 3. Seventy-five percent of patients in the
ischemic cohort had significant stenosis in the left anterior
descending coronary artery; 46% had three-vessel CAD. Seven
percent of patients included in the ischemic cohort had no
significant stenotic lesions at the time of index catheterization.
Of these patients, 93% had a history of myocardial infarction
and 58% had a history of coronary angioplasty or bypass
surgery. As specified in the subgroup definitions, no patient in
the nonischemic group had $75% stenosis in any epicardial
artery. Sixty-six percent of nonischemic patients had com-
pletely normal coronary arteries, whereas 19% had 25%
stenotic lesions and another 16% had 50% stenotic lesions.
Survival. Unadjusted Kaplan-Meier survival curves for
nonischemic patients, according to the degree of coronary
artery stenosis, are shown in Figure 2. Survival in patients with
nonischemic cardiomyopathy was similar, regardless of the
degree of coronary stenosis present (0%, 25% or 50%, p 5
0.39).
The results of a multivariable Cox proportional hazards
model are shown in Table 4. After adjustment for differences
in baseline characteristics, ischemic etiology remained a signif-
icant, independent predictor of mortality in these patients.
Other independent predictors of mortality included older age,






Age (yr) 55 (44, 65) 63 (55, 70)
Men 52 77
LVEF (%) 27 (20, 35) 32 (25, 37)
Symptomatic CHF 82 45
Duration of CHF symptoms (mo) 4 (1, 34) 5 (1, 36)




Family history of CAD 30 47
Peripheral vascular disease 4 15
Chest pain 44 86
Typical angina 34 58
Previous MI 0 67
Previous bypass surgery 0 20
Previous coronary angioplasty 0 15
Data are presented as percent of patients or medians (25th, 75th percen-
tiles). CAD 5 coronary artery disease; CHF 5 congestive heart failure; MI 5
myocardial infarction; NYHA 5 New York Heart Association.











*,75% stenosis of a major epicardial artery. Data are presented as percent
of patients. LAD 5 left anterior descending coronary artery; VD 5 vessel
disease.
Figure 2. Unadjusted Kaplan-Meier survival estimates for patients
with nonischemic cardiomyopathy and 0% coronary artery stenosis
(heavy solid line), 1% to 25% stenosis (light solid line) or 26% to 50%
stenosis (dashed line) (p 5 0.39).
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lower ejection fraction, previous symptomatic heart failure,
hypertension, diabetes, peripheral vascular disease, New York
Heart Association functional class IV heart failure symptoms
and typical angina.
Three interaction variables were also independent predic-
tors of mortality—ejection fraction by etiology (chi-square
statistic 7.9, p , 0.01), hypertension by etiology (chi-square
7.6, p , 0.01) and typical angina by etiology (chi-square 8.8,
p , 0.01). The prognostic effect of hypertension or typical
angina was reduced in the nonischemic group; that is, the
relation between these clinical features and mortality was more
pronounced in the ischemic group than in the group with
nonischemic cardiomyopathy. The prognostic effect of decreas-
ing ejection fraction was reduced in the nonischemic group; the
relation between lower ejection fraction and mortality was
more pronounced in the ischemic group than in the nonisch-
emic group.
Adjusted Kaplan-Meier survival curves depicting 5-year
survival in patients with ischemic and nonischemic cardiomy-
opathy are shown in Figure 3. Five-year survival was 0.59 and
0.69 for patients with ischemic and nonischemic cardiomyop-
athy, respectively (p , 0.0001).
Prognostic contribution of etiology and extent of CAD. The
prognostic contribution of etiology and extent of CAD, as
measured by the CAD index, is shown in Table 5. The CAD
index contributed more prognostic information to a model
including age, ejection fraction, history of symptomatic heart
failure, peripheral vascular disease, functional class IV symp-
toms and typical angina than did etiology of heart failure (total
model log likelihood chi-square 700 vs. chi-square 680, respec-
tively).
Adjusted Kaplan-Meier survival curves depicting 5-year
survival in patients with nonischemic cardiomyopathy and
ischemic cardiomyopathy divided into groups of mild, moder-
ate and severe CAD are shown in Figure 4. The 5-year survival
rate of ischemic patients with mild CAD was similar to that of
the nonischemic group (p 5 0.18). Ischemic patients with
moderate and severe CAD had increasing mortality rates.
Discussion
We followed up 3,787 patients with angiographically diag-
nosed ischemic (n 5 3,112) and nonischemic (n 5 675)
cardiomyopathy over 11 years. Five-year survival in patients
with ischemic cardiomyopathy was significantly lower than that
in nonischemic patients. In a multivariable Cox proportional
hazards model that adjusted for differences in baseline clinical
characteristics, ischemic etiology remained a significant predic-
tor of mortality. However, the extent of CAD, as measured by
the CAD index, contributed more prognostic information than






Age 215.2 0.044 0.003
Ejection fraction 160.5 20.024 0.008
Symptomatic CHF 39.5 0.392 0.062
Ischemic etiology 33.5 0.595 0.240
Hypertension 26.6 20.112 0.136
Diabetes 25.5 0.292 0.058
Peripheral vascular disease 23.7 0.344 0.071
NYHA functional class IV CHF‡ 11.0 0.242 0.073
Typical angina‡ 9.4 20.672 0.219
*Adjusted chi-square reflects the combination of the main factor and the interaction terms. †Coefficients presented
reflect main factors only. The coefficients and standard errors (SE) of the coefficients for the three interaction terms
ischemic by ejection fraction, ischemic by hypertension and ischemic by typical angina are 20.242 (SE 0.009), 0.405 (SE
0.147) and 0.672 (SE 0.226), respectively. ‡p , 0.01, all others p , 0.0001. Abbreviations as in Table 2.
Figure 3. Adjusted Kaplan-Meier survival estimates for patients with
nonischemic (solid line) and ischemic (dashed line) cardiomyopathy
(p , 0.0001).
Table 5. Prognostic Contribution of Ischemic Cardiomyopathy
Versus Extent of Coronary Artery Disease
Model Chi-Square
Baseline variables 665
Baseline plus ischemic etiology 680
Baseline plus CAD index 700
CAD index 5 Coronary Artery Disease Prognostic Index.
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did the clinical diagnosis of ischemic or nonischemic cardio-
myopathy.
Ischemic cardiomyopathy and mortality. Several investiga-
tors have studied the influence of heart failure etiology on
mortality (21–25). The Studies Of Left Ventricular Dysfunc-
tion (SOLVD) investigators (25) followed over 6,000 patients
with congestive heart failure for 1 year, 69% of whom had
ischemic cardiomyopathy. Their group had a clinical risk
profile similar to that of the current study group. Overall
mortality for patients in the SOLVD registry at 1 year was
18%, similar to the mortality rate in our investigation. In
contrast to the findings of the current investigation, however,
the etiology of heart failure (ischemic or nonischemic) in the
SOLVD registry did not influence mortality.
One possible explanation for why ischemic etiology was not
associated with increased mortality rates in the SOLVD regis-
try relates to their definition of ischemic cardiomyopathy. The
diagnosis of ischemic cardiomyopathy in the SOLVD registry
was based on clinical judgment. The protocol did not require
angiographic or noninvasive evidence of ischemia. Our data
highlight the difficulties of making a diagnosis without angio-
graphic results. Angina and the presence of risk factors asso-
ciated with ischemic heart disease are common in patients with
nonischemic cardiomyopathy and should not be exclusively
relied on to determine the etiology of left ventricular dysfunc-
tion.
Andersson and Waagstein (24) studied a large group of
Swedish patients with congestive heart failure and the group
was identified retrospectively with an administrative data base.
Patients with the International Classification of Disease, ninth
revision (ICD-9) diagnostic code for congestive heart failure
(n 5 2,711) were followed up for 5 years. The mean age of this
cohort was 58 years; 68% were men. Because of the retrospec-
tive design of this study, no information on left ventricular
function or functional class symptoms was reported. Cardiac
catheterization was not required to establish the etiology of
congestive heart failure. Subgroup analysis of 5-year survival
among patients with ischemic and nonischemic cardiomyopa-
thy showed that mortality was significantly higher in the
ischemic group (p , 0.0001). In agreement with our results,
the presence of ischemic heart disease was an independent
predictor of mortality after multiple regression analysis (p ,
0.0001). The 5-year mortality rate for all patients in this study
was 50%, which was higher than that in our investigation. This
probably reflects the method used to identify patients; all were
identified at the time of an emergency hospital admission. In
contrast, patients in our study were referred for routine cardiac
catheterization, many of which were performed on an outpa-
tient basis.
Both the SOLVD registry and the Swedish study contribute
to a better understanding of the natural course of congestive
heart failure. Both studies are limited, however, in their ability
to draw conclusions about the clinical course of ischemic and
nonischemic cardiomyopathy. It is very difficult to diagnose
ischemic cardiomyopathy reliably without performing coronary
angiography, because many clinical features commonly associ-
ated with this condition frequently appear in patients with
nonischemic disease. Only one other investigation has com-
pared the clinical course of angiographically diagnosed isch-
emic with that of nonischemic cardiomyopathy. Likoff et al.
(21) followed the clinical course of 201 patients with heart
failure to determine which clinical variables were the best
predictors of mortality. All patients underwent coronary an-
giography, the results of which were used to determine isch-
emic or nonischemic etiology. During the 10.8-month
follow-up period, the overall mortality rate was 42%; the
mortality rate among ischemic patients (n 5 121) was signifi-
cantly higher than that among nonischemic patients (n 5 80)
(p 5 0.005). This difference in survival between ischemic and
nonischemic patients is consistent with the findings of our
investigation.
Extent of CAD and ischemic cardiomyopathy. Although
the angiographic diagnosis of ischemic and nonischemic car-
diomyopathy does provide valuable prognostic information,
assessing the extent of CAD improves the ability to assess risk
in patients with left ventricular dysfunction. Our analysis
indicates that after adjusting for important baseline character-
istics, the prognostic contribution of the extent of CAD disease
is greater than that of the clinical diagnosis of ischemic or
nonischemic cardiomyopathy. Moreover, the mortality rate of
some patients with the clinical diagnosis of ischemic cardiomy-
opathy and only mild CAD is similar to that of patients in the
nonischemic group. In these cases—patients with left ventric-
ular dysfunction “out of proportion” to the extent of CAD—
the clinical diagnosis of ischemic cardiomyopathy provides
misleading information about expected outcomes.
These findings suggest that coronary angiography is an
important part of the assessment of patients with cardiomyop-
athy and should be considered in all patients with left ventric-
ular dysfunction. Such a diagnostic approach provides impor-
tant diagnostic and prognostic information; assists in
Figure 4. Adjusted Kaplan-Meier survival estimates for patients with
nonischemic cardiomyopathy (heavy solid line), ischemic cardiomyop-
athy with mild CAD (light dashed line), ischemic cardiomyopathy with
moderate CAD (light solid line) and ischemic cardiomyopathy with
severe CAD (heavy dashed line).
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identifying therapies likely to result in improved clinical out-
comes such as lipid-lowering therapy, smoking cessation, hor-
mone replacement therapy and revascularization for patients
with ischemic cardiomyopathy; and may be useful in evaluating
medications that may have important etiology-specific interac-
tions, such as amlodipine, amiodarone, bisoprolol and digoxin.
Clinical determinants of mortality. Prognostic models pro-
vide a means of assessing a patient’s risk of adverse clinical
outcomes and may influence clinical management. The model
we developed in this study is particularly important because it
represents a large group of patients with left ventricular
dysfunction who were followed for a relatively long period.
Moreover, the variables that were independent predictors of
mortality are commonly collected in patients with heart failure
(age, ejection fraction, history of symptomatic heart failure,
ischemic or nonischemic etiology, hypertension, diabetes mel-
litus, peripheral vascular disease, functional class IV symptoms
and angina).
Increasing age was the most powerful predictor of mortality
in our study cohort. This finding is supported by data from the
Framingham Heart Study (26) and other heart failure trials
(2,9,24). The Framingham Heart Study assessed the influence
of advancing age on mortality in an unselected group of 652
patients who developed heart failure between 1948 and 1988.
The risk of death among men and women increased by 27%
and 61%, respectively, per decade of age, establishing advanc-
ing age as an important predictor of mortality in such a
population.
Left ventricular ejection fraction and the severity of heart
failure symptoms were also important independent predictors
of mortality in our study. These findings are supported by
several heart failure trials (2,9,27–30). Cohn et al. (28) assessed
the influence of reduced left ventricular function on mortality
in 1,446 patients participating in the Veterans Administration
Heart Failure Trials (V-HeFT I and V-HeFT II). Reduced
ejection fraction was shown to be a powerful predictor of
mortality in patients with heart failure, especially for those
patients with very low ejection fractions (,25%).
Hypertension, diabetes mellitus and peripheral vascular
disease were all independent predictors of mortality in our
study cohort. Hypertension and diabetes are important precur-
sors to the development of heart failure (31) and are associated
with increased mortality (2,24,31). Such findings highlight the
importance of treating these conditions and preventing the
development of heart failure. Peripheral vascular disease and
angina reflect the presence of atherosclerosis and ischemic
heart disease. Their prognostic contribution to our mortality
model is therefore not surprising.
Study limitations. The major limitation of this study is
referral bias. The fact that all the patients with left ventricular
dysfunction were referred for cardiac catheterization limits our
ability to generalize with all such patients. This limitation,
however, is also one of the strengths of this study—the etiology
of left ventricular dysfunction in all patients was established by
cardiac catheterization (generally considered the “reference
standard”). Other studies directly comparing survival in these
two patient groups have not required cardiac catheterization to
establish the diagnosis (22,24,25). The study by Likoff et al.
(21), one of the few studies that did require cardiac catheter-
ization in all patients, included only 201 patients followed ,1
year. The present study, with .3,700 patients and much longer
follow-up, represents the largest data set studied to date
comparing outcomes in angiographically confirmed ischemic
and nonischemic cardiomyopathy.
Conclusions. Ischemic etiology is an independent predic-
tor of mortality in patients with left ventricular dysfunction.
However, the extent of CAD contributes more prognostic
information than the clinical diagnosis of ischemic or nonisch-
emic cardiomyopathy. Coronary angiography should be con-
sidered in all patients with left ventricular dysfunction, because
the results substantially contribute to diagnosis, prognosis and
management decisions. Further research is needed to refine
the clinical definition of ischemic cardiomyopathy so physi-
cians can appropriately prescribe treatment and accurately
predict outcome.
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